Tower Research Capital (TRC)’s bioAffinity Technologies BIAF Stock Holding History

Tower Research Capital (TRC)’s Portfolio BIAF Stock Details BIAF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.26K	Buy	432 +294	+213%	+$9.01K	﹤0.01%	4290
2026 Q1	$7.9K	Sell	138 -122	-47%	-$2.96K	﹤0.01%	3997
2025 Q4	$4.61K	Buy	260 +93	+56%	+$2.78K	﹤0.01%	4200
2025 Q3	$7.4K	Buy	167 +160	+2,286%	+$19.1K	﹤0.01%	4100
2025 Q2	$898	Hold	7	–	–	﹤0.01%	4918
2025 Q1	$817	Sell	7 -7	-50%	-$1.93K	﹤0.01%	4824
2024 Q4	$5.76K	Buy	14 +9	+180%	+$5.43K	﹤0.01%	4246
2024 Q3	$4.34K	Sell	5 -5	-50%	-$4.49K	﹤0.01%	4582
2024 Q2	$9.97K	Buy	10 +3	+43%	+$3.12K	﹤0.01%	4191
2024 Q1	$6.76K	Hold	7	–	–	﹤0.01%	4320
2023 Q4	$4.36K	Sell	7 -2	-22%	-$1.28K	﹤0.01%	4964
2023 Q3	$4.71K	Buy	9 +6	+200%	+$4.57K	﹤0.01%	4829
2023 Q2	$2.53K	Buy	+3	New	+$2.48K	﹤0.01%	5189
2022 Q4	–	Hold	0	–	–	–	5896
2022 Q3	–	Hold	0	–	–	–	6063

Other funds holding BIAF

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

JSSH

J. Safra Sarasin Holding $6.97B AUM 32.91% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Tower Research Capital (TRC)'s BIAF Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its bioAffinity Technologies (BIAF) stake by 213% in Q2 2026, buying an estimated $9.01K and bringing the position to 432 shares worth $5.26K. The position accounts for ﹤0.01% of the portfolio, ranked #4290.

Tower Research Capital (TRC) first reported a position in BIAF in Q2 2023 and has held it in 13 quarters since. The position peaked at $9.97K in Q2 2024. 19 funds tracked by Wall St. Rank hold BIAF as of Q2 2026.

Tower Research Capital (TRC) held 432 shares of bioAffinity Technologies worth $5.26K as of Q2 2026.
Tower Research Capital (TRC) bought 294 bioAffinity Technologies shares in Q2 2026, an estimated $9.01K.
bioAffinity Technologies made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4290 holding.
Tower Research Capital (TRC) first reported a position in bioAffinity Technologies in Q2 2023 and has held it in 13 quarters since.
Tower Research Capital (TRC)'s bioAffinity Technologies position peaked at $9.97K in Q2 2024.
19 funds tracked by Wall St. Rank held bioAffinity Technologies as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.